Bioconjugates of upconversion nanoparticles for cancer
biomarker detection

a 2025

Bioconjugates of upconversion nanoparticles for cancer biomarker detection

ŠPAČEK, Pavel; Ekaterina MAKHNEVA; Antonín HLAVÁČEK; Julie WEISOVÁ; Hans-Heiner GORRIS et al.

Základní údaje

Originální název

Bioconjugates of upconversion nanoparticles for cancer biomarker detection

Autoři

ŠPAČEK, Pavel; Ekaterina MAKHNEVA; Antonín HLAVÁČEK; Julie WEISOVÁ; Hans-Heiner GORRIS; Petr SKLÁDAL a Zdeněk FARKA

Vydání

24. Interdisciplinary meeting of young life scientists, 2025

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

10406 Analytical chemistry

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Označené pro přenos do RIV

ISSN

Klíčová slova anglicky

photon-upconversion nanoparticle; immunoassay; massively parallel spectroscopy; bioconjugation; biomarker; prostate-specific antigen; protein p53

Příznaky

Mezinárodní význam

Změněno: 23. 2. 2026 16:38, Mgr. Pavel Špaček

Anotace

V originále

Sensitive detection of clinical biomarkers is crucial for the diagnosis of numerous illnesses. High sensitivity is of the utmost importance in the case of cancer biomarkers, as monitoring slight changes in their concentrations allows for early-stage cancer diagnosis and the assessment of treatment response. Due to their high specificity conferred by antibodies, immunochemical assays have proven indispensable for biomarker detection. However, conventional immunoassay labels, such as enzymes or fluorophores, are typically not sensitive enough for the detection of low-abundance cancer biomarkers. To enhance sensitivity, various kinds of nanoparticles are often employed as labels. Photon-upconversion nanoparticles (UCNPs) stand out as one of the most promising options. These lanthanide-doped nanocrystals can convert near-infrared radiation into light of a shorter wavelength (anti-Stokes emission), significantly reducing the optical background. Moreover, their emission spectra can be easily tuned by altering the composition of dopant ions. In immunoassays, the heterogeneous assay format is typically preferred due to its high specificity and sensitivity. These desirable properties are ensured by immobilization and washing steps, which significantly prolong the procedure. On the other hand, homogeneous immunoassays omit these time-consuming steps; however, this comes at the cost of reduced specificity and sensitivity. To combine the advantages of each assay format, we have developed a novel artificial intelligence-aided homogeneous immunoassay based on massively parallel spectroscopy (MPS). This single-molecule method utilizes two different UCNP–antibody labels with distinct emission spectra binding to the analyte molecule; only sandwich immunocomplexes containing the analyte molecule and both labels are detected. We have successfully employed MPS in assays for prostate-specific antigen and protein p53, two important cancer biomarkers. This immunoassay format was utilized for the first time, showing strong potential to become a convenient and high-throughput method for biomarker detection.

Citovat

ŠPAČEK, Pavel; Ekaterina MAKHNEVA; Antonín HLAVÁČEK; Julie WEISOVÁ; Hans-Heiner GORRIS; Petr SKLÁDAL a Zdeněk FARKA. Bioconjugates of upconversion nanoparticles for cancer biomarker detection. In 24. Interdisciplinary meeting of young life scientists. 2025. ISSN 2336-7210.

@proceedings{2556305,
   author = {Špaček, Pavel and Makhneva, Ekaterina and Hlaváček, Antonín and Weisová, Julie and Gorris, HansandHeiner and Skládal, Petr and Farka, Zdeněk},
   booktitle = {24. Interdisciplinary meeting of young life scientists},
   keywords = {photon-upconversion nanoparticle; immunoassay; massively parallel spectroscopy; bioconjugation; biomarker; prostate-specific antigen; protein p53},
   language = {eng},
   title = {Bioconjugates of upconversion nanoparticles for cancer biomarker detection},
   url = {http://www.ccsss.cz/index.php/ccsss/issue/view/50/90},
   year = {2025}
}

TY  - CONF
ID  - 2556305
AU  - Špaček, Pavel - Makhneva, Ekaterina - Hlaváček, Antonín - Weisová, Julie - Gorris, Hans-Heiner - Skládal, Petr - Farka, Zdeněk
PY  - 2025
TI  - Bioconjugates of upconversion nanoparticles for cancer biomarker detection
KW  - photon-upconversion nanoparticle
KW  - immunoassay
KW  - massively parallel spectroscopy
KW  - bioconjugation
KW  - biomarker
KW  - prostate-specific antigen
KW  - protein p53
UR  - http://www.ccsss.cz/index.php/ccsss/issue/view/50/90
N2  - Sensitive detection of clinical biomarkers is crucial for the diagnosis of numerous illnesses. High sensitivity is of the utmost importance in the case of cancer biomarkers, as monitoring slight changes in their concentrations allows for early-stage cancer diagnosis and the assessment of treatment response. Due to their high specificity conferred by antibodies, immunochemical assays have proven indispensable for biomarker detection. However, conventional immunoassay labels, such as enzymes or fluorophores, are typically not sensitive enough for the detection of low-abundance cancer biomarkers. To enhance sensitivity, various kinds of nanoparticles are often employed as labels. Photon-upconversion nanoparticles (UCNPs) stand out as one of the most promising options. These lanthanide-doped nanocrystals can convert near-infrared radiation into light of a shorter wavelength (anti-Stokes emission), significantly reducing the optical background. Moreover, their emission spectra can be easily tuned by altering the composition of dopant ions. In immunoassays, the heterogeneous assay format is typically preferred due to its high specificity and sensitivity. These desirable properties are ensured by immobilization and washing steps, which significantly prolong the procedure. On the other hand, homogeneous immunoassays omit these time-consuming steps; however, this comes at the cost of reduced specificity and sensitivity. To combine the advantages of each assay format, we have developed a novel artificial intelligence-aided homogeneous immunoassay based on massively parallel spectroscopy (MPS). This single-molecule method utilizes two different UCNP–antibody labels with distinct emission spectra binding to the analyte molecule; only sandwich immunocomplexes containing the analyte molecule and both labels are detected. We have successfully employed MPS in assays for prostate-specific antigen and protein p53, two important cancer biomarkers. This immunoassay format was utilized for the first time, showing strong potential to become a convenient and high-throughput method for biomarker detection.
ER  -

ŠPAČEK, Pavel; Ekaterina MAKHNEVA; Antonín HLAVÁČEK; Julie WEISOVÁ; Hans-Heiner GORRIS; Petr SKLÁDAL a Zdeněk FARKA. Bioconjugates of upconversion nanoparticles for cancer biomarker detection. In \textit{24. Interdisciplinary meeting of young life scientists}. 2025. ISSN~2336-7210.

Přehled o publikaci